Last reviewed · How we verify
Extended treatment of symptomatic venous thromboembolism to reduce recurrence in adult patients with cancer
Approved treatments
- Fragmin · Pfizer Inc.
Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Extended treatment of symptomatic venous thromboembolism to reduce recurrence in adult patients with cancer patent landscape — cliff calendar, originator estates, attackable patents
- Extended treatment of symptomatic venous thromboembolism to reduce recurrence in adult patients with cancer treatment landscape brief
- Extended treatment of symptomatic venous thromboembolism to reduce recurrence in adult patients with cancer treatment updates RSS
Frequently asked questions about Extended treatment of symptomatic venous thromboembolism to reduce recurrence in adult patients with cancer
What drugs treat Extended treatment of symptomatic venous thromboembolism to reduce recurrence in adult patients with cancer?
Tracked treatments include Fragmin.
What is the treatment for Extended treatment of symptomatic venous thromboembolism to reduce recurrence in adult patients with cancer?
Standard treatment for Extended treatment of symptomatic venous thromboembolism to reduce recurrence in adult patients with cancer includes Fragmin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Extended treatment of symptomatic venous thromboembolism to reduce recurrence in adult patients with cancer patent cliff · Extended treatment of symptomatic venous thromboembolism to reduce recurrence in adult patients with cancer CI report
- Treatment: Fragmin · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing